# A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

> **NCT02377362** · PHASE1 · TERMINATED · sponsor: **GLWL Research Inc.** · enrollment: 74 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GLWL-01, Part A
- **DRUG:** Placebo, Part A
- **DRUG:** GLWL-01, Part B
- **DRUG:** Placebo, Part B
- **DRUG:** GLWL-01, Part C
- **DRUG:** Placebo, Part C

## Key facts

- **NCT ID:** NCT02377362
- **Lead sponsor:** GLWL Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2016-11-09
- **Final completion:** 2016-11-09
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** Insufficient efficacy for this indication. The study stopped after Part B.
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02377362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02377362, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02377362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*